169 related articles for article (PubMed ID: 16978199)
21. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
22. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
23. Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast.
Lester T; Wang J; Bourne P; Yang Q; Fu L; Tang P
Ann Clin Lab Sci; 2009; 39(1):17-24. PubMed ID: 19201736
[TBL] [Abstract][Full Text] [Related]
24. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.
Rakha EA; El-Rehim DA; Paish C; Green AR; Lee AH; Robertson JF; Blamey RW; Macmillan D; Ellis IO
Eur J Cancer; 2006 Dec; 42(18):3149-56. PubMed ID: 17055256
[TBL] [Abstract][Full Text] [Related]
25. Mesothelial markers in high-grade breast carcinoma.
Duhig EE; Kalpakos L; Yang IA; Clarke BE
Histopathology; 2011 Nov; 59(5):957-64. PubMed ID: 22092407
[TBL] [Abstract][Full Text] [Related]
26. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast.
Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S
Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440
[TBL] [Abstract][Full Text] [Related]
27. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.
Rakha EA; El-Sayed ME; Green AR; Paish EC; Lee AH; Ellis IO
Histopathology; 2007 Mar; 50(4):434-8. PubMed ID: 17448018
[TBL] [Abstract][Full Text] [Related]
28. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer.
Laakso M; Tanner M; Nilsson J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Bergh J; Isola J
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4185-91. PubMed ID: 16857790
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
[TBL] [Abstract][Full Text] [Related]
30. CD109 expression in basal-like breast carcinoma.
Hasegawa M; Moritani S; Murakumo Y; Sato T; Hagiwara S; Suzuki C; Mii S; Jijiwa M; Enomoto A; Asai N; Ichihara S; Takahashi M
Pathol Int; 2008 May; 58(5):288-94. PubMed ID: 18429827
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
32. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
[TBL] [Abstract][Full Text] [Related]
33. An immunohistochemical panel to differentiate metastatic breast carcinoma to skin from primary sweat gland carcinomas with a review of the literature.
Rollins-Raval M; Chivukula M; Tseng GC; Jukic D; Dabbs DJ
Arch Pathol Lab Med; 2011 Aug; 135(8):975-83. PubMed ID: 21809988
[TBL] [Abstract][Full Text] [Related]
34. Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy.
Goldstein NS; Decker D; Severson D; Schell S; Vicini F; Margolis J; Dekhne NS
Cancer; 2007 Oct; 110(8):1687-96. PubMed ID: 17722109
[TBL] [Abstract][Full Text] [Related]
35. Basal cytokeratin expression in relation to biological factors in breast cancer.
Kuroda H; Ishida F; Nakai M; Ohnisi K; Itoyama S
Hum Pathol; 2008 Dec; 39(12):1744-50. PubMed ID: 18755493
[TBL] [Abstract][Full Text] [Related]
36. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
37. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
39. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
40. High-grade carcinomas of the breast showing patterns of mixed ductal and myoepithelial differentiation (including myoepithelial cell-rich carcinoma of the breast).
Coyne JD; Dervan PA; Barr L
Histopathology; 2004 Jun; 44(6):580-4. PubMed ID: 15186273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
